Explore our work

The client requested support in planning short- and long-term HEOR strategies.

Since indications were rare diseases with limited existing data on the population, developing an evidence base required a unique approach, including planning natural history studies, registry-based analyses, and de novo data collection.

We collaborated with the client to develop a customized strategy to build an evidence base for pipeline indications and a custom integrated evidence platform (IEP) that boosted internal communication and knowledge management across the global organization.

A new drug was being investigated in a single arm study to evaluate its efficacy and safety in MM participants. The client identified a need to generate evidence on the standard of care, which could be done by creating an external control arm using real-world data.

RPR was used to obtain key KOL and payer insights on the appropriate study design elements required to create a robust external control arm.

Within three weeks, RPR was able to gather robust insights that allowed clients to identify best and worst practices for designing an ECA and understand that the publication of final results in a peer-reviewed journal was considered the most crucial evidence.